Monte Rosa Therapeutics (GLUE) to Release Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect Monte Rosa Therapeutics to post earnings of ($0.45) per share and revenue of $17.09 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

Monte Rosa Therapeutics Price Performance

NASDAQ:GLUE opened at $17.06 on Thursday. The company has a market cap of $1.11 billion, a price-to-earnings ratio of 53.31 and a beta of 1.63. Monte Rosa Therapeutics has a 1 year low of $3.50 and a 1 year high of $25.77. The stock’s 50 day simple moving average is $20.07 and its two-hundred day simple moving average is $14.36.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GLUE. TD Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Piper Sandler reiterated an “overweight” rating and issued a $37.00 price target (up from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Wells Fargo & Company boosted their price objective on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $31.00 price target on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.80.

Insider Buying and Selling at Monte Rosa Therapeutics

In related news, insider Edmund Dunn sold 25,164 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $18.10, for a total value of $455,468.40. Following the transaction, the insider owned 22,693 shares of the company’s stock, valued at $410,743.30. This trade represents a 52.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Markus Warmuth sold 5,466 shares of Monte Rosa Therapeutics stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the sale, the chief executive officer owned 613,471 shares of the company’s stock, valued at $10,993,400.32. The trade was a 0.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 36,771 shares of company stock valued at $693,692. Corporate insiders own 6.90% of the company’s stock.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GLUE. Price T Rowe Associates Inc. MD raised its stake in Monte Rosa Therapeutics by 10.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,118,904 shares of the company’s stock worth $80,265,000 after buying an additional 481,844 shares in the last quarter. State Street Corp raised its position in shares of Monte Rosa Therapeutics by 148.9% in the 4th quarter. State Street Corp now owns 2,107,480 shares of the company’s stock worth $33,045,000 after acquiring an additional 1,260,707 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Monte Rosa Therapeutics by 459.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after acquiring an additional 1,054,406 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Monte Rosa Therapeutics by 4.6% during the 4th quarter. Geode Capital Management LLC now owns 1,204,844 shares of the company’s stock worth $18,896,000 after purchasing an additional 53,278 shares during the last quarter. Finally, MPM Bioimpact LLC bought a new stake in Monte Rosa Therapeutics during the fourth quarter valued at about $18,399,000. 79.96% of the stock is currently owned by institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.